EUVIMEDEUVIMED entdecken
CrossrefInfokarte

From Plasma to Whole Blood: Validation of Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) As Accessible Biomarkers in Stroke

Yuting Xue, Yinwei Gu, Jiajing Wu, Yufeng Sun, Xilong Wang, Jing Jin, Xiangyi Liu

The Journal of Applied Laboratory Medicine · 2026-11-04 · 11 (6) · 1392-1405

DOI: 10.1093/jalm/jfag113 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are critical blood-based biomarkers for the diagnosis and monitoring of a wide range of central nervous system (CNS) injuries. Current plasma-based assays require centrifugation, which prolongs turnaround time (TAT) and limits utility in emergency settings. This study aimed to develop and validate a rapid, automated chemiluminescence immunoassay for the direct quantification of GFAP and NfL in whole blood. Methods We used a dual-antibody sandwich chemiluminescence immunoassay to measure GFAP and NfL. The assay was optimized for whole blood through adjustments of reagent formulation and implementation of a hematocrit (HCT) correction algorithm. Performance was evaluated in terms of precision, linearity, limit of quantification, and interference. In total, 115 paired whole blood and plasma samples from 78 acute stroke patients were analyzed to assess diagnostic accuracy. Results The HCT correction algorithm effectively minimized measurement bias across a wide HCT range (35%–55%). Precision of GFAP and NfL in whole blood and plasma showed coefficients of variation below 5% across a broad concentration range. Excellent correlations were observed between whole blood (HCT-corrected) and plasma measurements for both GFAP (R2 = 0.990) and NfL (R2 = 0.955). Diagnostic accuracy for distinguishing hemorrhagic from ischemic stroke was comparable between whole blood and plasma (AUC 0.86 vs 0.84, P = 0.58) in this population. Conclusions The novel GFAP and NfL whole-blood assay, due to its shorter TAT, high consistency with plasma, and broad analytical range, demonstrated the potential to accelerate stroke triage in acute care settings.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →